Business
Medincell: New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile – No PDSS Observed
MONTPELLIER, France, September 22, 2025--Regulatory News: Medincell (Paris:MEDCL):
About this update from Teva Pharmaceutical Industries Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1772,"height":295,"url":"https://media.zenfs.com/en/business-wire.com/80c45c9ed1184142267014f8d738f57f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9W__I8nQLdOkT_33yHjIrA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/80c45c9ed1184142267014f8d738f57f","width":960,"height":160},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/dxyJZxqVFzdMNQTUHG4N4g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTEwNztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/80c45c9ed1184142267014f8d738f57f","width":640,"height":107},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/SPRngw9m_hyhCiSnyyrs8g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/80c45c9ed1184142267014f8d738f57f","width":1200,"height":200}},"lazy":false},{"type":"text","content":"There were no suspected or confirmed PDSS (Post-injection Delirium/Sedation Syndrome)1 events observed with Medincell’s Olanzapine LAI through week 56 in the pivotal Phase 3 SOLARIS trial2","length":188,"tagName":"p"},{"type":"text","content":"The long-term systemic safety profile was consistent with other olanzapine formulations2","length":88,"tagName":"p"},{"type":"text","content":"Teva plans to proceed with an NDA submission of Olanzapine LAI in the US in Q4 2025","length":83,"tagName":"p"},{"type":"text","content":"The new data were showcased in one of ten schizophrenia-related posters presented by Medincell’s partner, Teva, at the 2025 Psych Congress, held from September 17 to 21 in San Diego, California","length":193,"tagName":"p"},{"type":"text","content":"MONTPELLIER, France, September 22, 2025--(BUSINESS WIRE)--Regulatory News:","length":74,"tagName":"p"},{"type":"text","content":"Medincell (Paris:MEDCL):","length":24,"tagName":"p"},{"type":"text","content":"Olanzapine LAI (mdc-TJK / TEV-‘749) is an investigational, once-monthly, subcutaneous long-acting injection of the atypical antipsychotic olanzapine for the treatment of schizophrenia. This is the second product within the Teva partnership – after UZEDY® approved by the FDA in April 2023 – that uses Medincell’s co-polymer technology (licensed to Teva under the name SteadyTeq™) to generate a controlled steady...